

EuroEyes

International Newsletter no.8



Århus | Berlin | Beijing | Copenhagen | Düsseldorf | Frankfurt | Hamburg | Hong Kong | Munich | Shanghai | Shenzhen | ...

The 8340th patient, Ms. Meesenburg: „A piece of freedom that cannot be paid for with money.“




EuroEyes surpassed the whole of 2019 with 8,340 interested persons on October 20th.

On October 20th 2020 - Euroeyes Germany celebrated 8340 pre-operations consultations thereby surpassed the numbers of whole year of 2019.

On November 6th, Dr. Ralf Christian Lerche, deputy medical director, successfully treated our 8,340th patient, Cornelia Meesenburg with a trifocal lens exchange and solemnly presented her with a bouquet of thanks for her trust in EuroEyes.

Treatment of “Young” Presbyopic patients: First ICL (EDOF) to be implanted in EuroEyes Hamburg December 2020



EuroEyes is pleased to announce soon to Implant the first ICL EDOF lens for presbyopia. (trade name: EVO Viva ICL Lens) from Staar Surgical. This represents a new treatment option for young myopic people (age 40-50, - 1,0 to -18,0 dpt. without Astigmatism) sufferings presbyopia who are complaining of reading glasses or progressive glasses.

Read the full article here: <http://www.euroeyes.com/news/>

Employments benefits by way of restricted shares


EuroEyes is listed on the HKEX for more than a year now – our employees can participate via Restricted Shares (RSU)

EuroEyes International Eye Clinic Ltd. is listed at the Hong Kong Stock Exchange since October 15th 2019 and since then our employees can become shareholders of the company via RSU. RSU are regular shares of EuroEyes which are granted to our employees in most cases without any consideration. The only restriction, so called vesting condition, they have to fulfil: don't sell these EuroEyes shares for a certain period, in most cases one or two years.

More than 5% of our employees have opted for RSU in 2020. They have shown their faith in positive development of the group by choosing RSU instead of a cash payment for their achievements. Every increase in our share price immediately increases the value of their RSU. The administration of these RSUs is handled by a bank engaged by us, so that the employees don't have to do anything in that respect.

We are looking forward to an increased number of employees, who believe in the successful future of EuroEyes and choose RSU to show it.





EuroEyes Germany achieved a record number of Eye surgeries in October 2020!

Refractive surgery has proven to be particularly resilient under COVID-19 conditions. During the pandemic, it has become even more apparent that glasses are annoying when wearing a mask or in video conferences. That is why more and more people want to get rid of their glasses. Already in October 2020 EuroEyes was able to achieve a record level of eye surgeries, with + 43% more operations than in the previous year and increase of + 12% compared to the previous month. Through mouth-to-mouth, 3 to 4 additional bookings follow each happy patient within 6-12 months. In order to meet the increasing demand, EuroEyes is hiring employees at all levels to increase capacities.

More: <https://www.euroeyes.com/euroeyes-achieved-a-record-number-of-eye-surgeries-in-october-2020/>



EuroEyes update on Corona

For ten months now, the global corona pandemic with all its economic, political and, last but not least, considerable private restrictions has kept us in suspense.

At EuroEyes, our greatest concern is the protection of our patients and employees. Therefore, we have developed comprehensive hygiene concepts and changes in the context of appointments and room use. Temperature measurements, a specific anamnesis and, if necessary, the implementation of quick antigen tests on site allow us to quickly assess the current situation.

Unfortunately, we have to reduce the number of contacts, among other things, by restricting the admission of accompanying persons. We are in constant communication with health authorities and hygiene committees, our approach is continuously adapted to the current situation and requirements. Thanks to modern room air concepts, we achieve the highest level of safety in the operating theaters. Thanks to these adjustments, the continuation of the processes in our clinics is almost normal.

Fortunately, to this day we have not had any infections at EuroEyes. We wish all patients and employees a healthy autumn and winter.



OK lenses in Children – Treatment in China

Myopia is the most common type of refractive error in China and even in the world. In recent decades, the incidence of myopia has been increasing at a younger age. The number of students in China is the highest in the world, with myopia rate reaching about 50% to 60%. For a long time, EuroEyes has been paying close attention to the vision health of young people, hoping to help them control myopia through OK lenses.

Orthokeratology lens, commonly known as OK lens, is a kind of rigid contact lens worn at night to achieve clear vision during the day without the need for glasses, and long-term use can slow the development of myopia.

International studies have proven that OK lenses have a great effect on myopia control than frame lenses and soft contact lenses, and are now recognized as one of the most effective ways to prevent and control myopia, which must be fitted in a professional medical institution and require a detailed eye examination before being fitted.

Happy Holidays

We would like to thank all patients, interested parties, partners and employees for the trust they have placed in us this year and the pleasant, successful cooperation.

Enjoy reflective holidays with your loved ones and have a good New Year! Stay healthy.

Editorial Office

You can reach us here: marketing@euroeyes.de

Editorial Management:

Dr. Jørn Jørgensen, founder of EuroEyes

Text: Dr. J. Jørgensen, PD Dr. R.-C. Lerche,

Dr. M. Braun, M. Cersovsky, J. Giriskén, M. Zhang

Graphic and Layout:

J. Giriskén, Graphic and Design

Photo and Video Assistant:

S. Savalanpour, Graphic Student

Mailing Functionality:

T. Franzen, Online Marketing

EuroEyes Deutschland Holding GmbH & Co. KG

Valentinskamp 90, 20355, Hamburg, Germany
Managing Director: Dr. med. Jørn S. Jørgensen
Amtsgericht Hamburg HRA 124184
USt-ID: DE320103260

Komplementärin:
EuroEyes Deutschland Verwaltung GmbH
Amtsgericht Hamburg HRB 155851

Managing Director:
Dr. med. Jørn S. Jørgensen | Dr. Markus Braun

Phone: +49 40 8664 887-0
www.euroeyes.com | [Datenschutz](#) | [Impressum](#)

0800 1711 1711
service@euroeyes.de